Skip to main content


Table 3 Alemtuzumab patient demographical data for whom only morbidity and current conventional synthetic or biological DMARD therapy data was obtained

From: Immune reconstitution 20 years after treatment with alemtuzumab in a rheumatoid arthritis cohort: implications for lymphocyte depleting therapies

  Age (Years) Sex Disease Duration (Years) Alemtuzumab total dose (mg) DMARD/Biological therapy
CAM14 68 F 35 62 MTX
CAM15 69 M 23 400 HCQ
CAM16 75 F 26 260 MTX, HCQ
CAM24 63 M 43 2 ADA
  1. MTX - methotrexate; HCQ – hydroxychloroquine; ADA – adalimumab